GlassScriptPhysician profile
Jason Rigdon
NPI 1952931867
$1,200.65
in general payments reported to CMS, 2019-2025
18 companies · $15.17 in 2025
The $15.17 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $855 · 2022: $243 · 2023: $87.32 · 2025: $15.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $102.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $350.21 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.24 | 2021-2022 | |
| Exelixis INC. | $168.08 | 2021 | |
| Servier Pharmaceuticals LLC | $77.60 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $73.68 | 2021 | |
| Astellas Pharma US INC | $67.09 | 2021 | |
| Daiichi Sankyo INC. | $58.77 | 2021 | |
| Eisai INC. | $46.11 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $41.03 | 2021 | |
| Sirtex Medical INC | $22.71 | 2023 | Sir-Spheres Microspheres |
| Myriad Genetic Laboratories, INC. | $17.26 | 2021 | |
| Incyte Corporation | $17.20 | 2021 | |
| Merck Sharp & Dohme LLC | $17.10 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.60 | 2021 | |
| Janssen Biotech, INC. | $15.17 | 2025 | Rybrevant, Carvykti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $15.11 | 2021 | |
| Amgen INC. | $14.30 | 2021 | |
| Gilead Sciences, INC. | $13.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Rigdon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.